On Thursday, Cathie Wood-led Ark Invest executed significant trades involving Amazon.com Inc. (NASDAQ:AMZN)  , Baidu Inc. (NASDAQ:BIDU) , and Salesforce Inc. (NYSE:CRM) .The Amazon TradeThe Baidu TradeBaidu’s stock dropped following its quarterly results. The Chinese tech giant’s recent earnings report revealed a 4% year-over-year revenue decline, yet the company continues to invest in AI.The Salesforce TradeARKW fund sold 15,622 shares of Salesforce valued at approximately $3.1 million based on the closing ...

U.S. stocks were lower, with the Nasdaq Composite falling more than 400 points on Thursday.Shares of J M Smucker Co (NYSE:SJM) rose sharply during Thursday's session after the company reported better-than-expected third-quarter financial results.Adjusted earnings per share $2.38, beating the $2.27 estimate. Net sales increased 7% to $2.339 billion from $2.186 billion a year earlier, topping the $2.322 billion estimate.Smucker shares jumped 8.5% to $115.65 on Thursday.Here are some other big stocks recording ...

分组1 - Claritev Corporation reported a quarterly loss of $4.88 per share, which was worse than the Zacks Consensus Estimate of a loss of $3.96, representing an earnings surprise of -23.23% [1] - The company posted revenues of $246.55 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 2.13%, and showing an increase from $232.15 million year-over-year [2] - Claritev Corporation has surpassed consensus revenue estimates four times over the last four quarters, but has only exceeded consensus EPS estimates once during the same period [2] 分组2 - The stock has underperformed significantly, losing about 45.6% since the beginning of the year, while the S&P 500 has gained 0.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$3.75 on revenues of $243.21 million, and for the current fiscal year, it is -$14.26 on revenues of $992.62 million [7] - The Medical Info Systems industry, to which Claritev Corporation belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Insights - Butterfly Network, Inc. (NYSE:BFLY) is recognized as a strong buy penny stock, recently achieving GovRAMP and TX-RAMP authorizations for its Butterfly iQ+/iQ3 and Compass AI™ ultrasound solutions, enabling sales to government agencies [1][2] - The company reported a 17% year-over-year revenue growth for Q4, amounting to $26.2 million, surpassing the Street's estimate of $25.7 million, with a full-year revenue of $92.3 million [3] Group 1: Company Developments - The GovRAMP Authorization demonstrates Butterfly Network's commitment to high compliance and security standards, while TX-RAMP Certification is specific to Texas, the only state requiring standalone authorization [2] - Butterfly Network specializes in digital health, focusing on intuitive software and semiconductor-based ultrasound technology, with two portable devices available: Butterfly iQ3 and Butterfly iQ+ [4] Group 2: Market Performance - Craig-Hallum raised the price target for Butterfly Network from $3.25 to $5.25 while maintaining a Buy rating, reflecting confidence in the company's growth trajectory [3]

Company Overview - Butterfly Network, Inc. (NYSE:BFLY) specializes in handheld ultrasound devices that facilitate whole-body imaging through a single probe connected to smartphones and computers [2]. Market Analysis - The market for medical devices, particularly ultrasound technology, is highly competitive, making it challenging for companies like Butterfly Network to gain a foothold [1]. - Even established players like GE Healthcare have reported strong numbers, but their stock performance remains volatile, indicating a tough environment for new entrants [1]. Investment Perspective - While there is potential for Butterfly Network as an investment, certain AI stocks are perceived to offer greater upside potential with less downside risk [3]. - The article suggests that investors may find better opportunities in undervalued AI stocks that could benefit from current economic trends, such as tariffs and onshoring [3].

Core Insights - Butterfly Network, Inc. has achieved GovRAMP and TX-RAMP Authorizations for its Butterfly iQ+/iQ3 and Compass AI ultrasound solutions, enabling the company to sell cloud services to state and local government agencies, including in Texas [1] Group 1 - The company specializes in digital health, focusing on semiconductor chip-based ultrasound devices, software, and AI [1] - The certifications obtained will expand the company's market reach to government agencies [1]

Group 1 - Butterfly Network, Inc. (NYSE:BFLY) has received positive ratings from analysts, with Craig-Hallum raising the price target to $5.25 from $3.25 and maintaining a Buy rating, while Lake Street raised its target to $5.50 from $4, also reiterating a Buy rating [1][2] - The company reported a year-over-year revenue growth of at least 17% for Q4, amounting to $26.2 million, surpassing the Street's estimate of $25.7 million, with a full-year revenue of $92.3 million [1][3] - The growth is primarily attributed to the core business, with some revenue in Q4 coming from a partnership with Midjourney [1] Group 2 - Butterfly Network specializes in digital health, focusing on transforming care through software and semiconductor-based ultrasound technology, with two portable ultrasound devices available: Butterfly iQ3 and Butterfly iQ+ [4] - The company's Ultrasound-on-Chip technology enables whole-body imaging using a single handheld probe, showcasing innovation in the ultrasound market [4]

Core Viewpoint - Lake Street analyst Ben Haynor has raised the price target for Butterfly Network (BFLY) to $5.50 from $4, maintaining a Buy rating on the shares, indicating a positive outlook for the company's stock performance [1] Group 1 - The firm anticipates that both healthcare and non-healthcare investors will recognize the "platform payoff" from various areas of Butterfly Network's business becoming more apparent [1] - The analyst expects multiple expansion for the company this year, supporting the rationale behind the increased price target [1]

Group 1 - Assertio (ASRT) is a stock that has gained about 14% year-to-date, outperforming the average gain of 7% in the Medical group [4] - Assertio is ranked 8 in the Zacks Sector Rank, which evaluates 932 companies within the Medical sector [2] - The Zacks Rank for Assertio is 1 (Strong Buy), indicating a positive earnings outlook with a 6.6% increase in the full-year earnings estimate over the past quarter [3] Group 2 - Assertio belongs to the Medical - Drugs industry, which has 141 stocks and is currently ranked 96 in the Zacks Industry Rank, with an average gain of 1.9% year-to-date [5] - Another outperforming stock in the Medical sector is Butterfly Network, Inc. (BFLY), which has returned 15.8% year-to-date and has a Zacks Rank of 2 (Buy) [4][5] - The Medical Info Systems industry, to which Butterfly Network belongs, has 42 stocks and is currently ranked 168, with a year-to-date gain of 2% [6]

Core Viewpoint - Butterfly Network, Inc. is set to participate in the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 12-15, 2026, in San Francisco, California [1]. Company Participation - The company's leadership team, including Joseph DeVivo (President, CEO & Chairman) and John Doherty (Executive Vice President & CFO), will represent Butterfly Network at the conference [1].